Table 3.
Association of APOE ε4 count with cognition
| Models | Independent variable | Outcome | |
|---|---|---|---|
| Global Cognitive function | AD dementia | ||
| Estimated effect (95% CI), p-value | OR (95% CI), p-value | ||
| Model 1a | APOE ε4 | −0·57 (−0·71 to −0·42), p=1·3×10−14 | 2·4 (1·8 to 3·1), p=9·6×10−12 |
| Model 2a | APOE ε4 (adj Aβ +PHFtau) | −0·18 (−0·31 to −0·04), p=0·010 | 1·4 (1·01 to 1·9), p=0·042 |
| Model 3b | APOE ε4 (adj Aβ +PHFtau + LB) | −0·17 (−0·31 to −0·04), p=0·010 | 1·4 (1·004 to 1·9), p=0·047 |
| Model 4a | APOE ε4 (adj Aβ +PHFtau + TDP-43 stage) | −0·13 (−0·27 to −0·001), p=0·048 | 1·2 (0·9 to 1·7), p=0·19 |
| Model 5c | APOE ε4 (adj Aβ +PHFtau + TDP-43 burden) | −0·09 (−0·22 to 0·04), p=0·18 | 1·2 (0·9 to 1·7), p=0·29 |
Estimated effects (adjusted difference in global cognitive function per each additional APOE ε4 allele) were reported from linear regressions with global cognitive function proximate to death as the outcome, and ORs of AD dementia for each additional APOE ε4 allele were reported from logistic regressions with AD dementia as the outcome. In model 1, APOE ε4 count was the independent variable and age at death, sex, and years of education were controlled. Aβ and PHFtau were additionally controlled in model 2, and LB stage was also controlled in model 3. TDP-43 stage or TDP-43 burden was adjusted in addition to Aβ, PHFtau, age at death, sex, and years of education in model 4 and 5, respectively.
n=1,038 for global cognitive function, n=1,033 for AD dementia.
n=1,036 for global cognitive function, n=1,031 for AD dementia.
n=1,021 for global cognitive function, n=1,016 for AD dementia. Aβ=β-amyloid, AD=Alzheimer’s disease, adj=adjusted for, CI=confidence interval, LB= Lewy body pathology (stage), OR=odds ratio, PHFtau=paired helical filament tau, TDP-43=TAR-DNA binding protein-43kDa proteinopathy.